Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26968359

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Apr
First author
Aluwini S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Apr;17(4):406-407. doi: 10.1016/S1470-2045(15)00626-9.
    note
    Source null
    related pmid
    26968358
    relationship
    Comment in

Authors and identifiers

  1. name
    Aluwini S
    type
    Author
  2. name
    Pos F
    type
    Author
  3. name
    Schimmel E
    type
    Author
  4. name
    Krol S
    type
    Author
  5. name
    van der Toorn PP
    type
    Author
  6. name
    de Jager H
    type
    Author
  7. name
    Alemayehu WG
    type
    Author
  8. name
    Heemsbergen W
    type
    Author
  9. name
    Heijmen B
    type
    Author
  10. name
    Incrocci L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Aluwini S
    type
    Author
  2. name
    Pos F
    type
    Author
  3. name
    Schimmel E
    type
    Author
  4. name
    Krol S
    type
    Author
  5. name
    van der Toorn PP
    type
    Author
  6. name
    de Jager H
    type
    Author
  7. name
    Alemayehu WG
    type
    Author
  8. name
    Heemsbergen W
    type
    Author
  9. name
    Heijmen B
    type
    Author
  10. name
    Incrocci L
    type
    Author
bibliography ids
  1. nci-bib-2d1f1f7a10428f469e847933
book metadata
content sha256
6e2096ac9feab8d3fa2801e3b1a82d48a49ec70c3df7516934a718f88343bf7c
document type
citation
dois
  1. 10.1016/S1470-2045(15)00567-7
electronic publication date
display
2016 Mar 9
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:26968359
immutable id
pubmed:26968359@6e2096ac9feab8d3fa2801e3b1a82d48a49ec70c3df7516934a718f88343bf7c
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
464-474
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Apr;17(4):406-407. doi: 10.1016/S1470-2045(15)00626-9.
    note
    Source null
    related pmid
    26968358
    relationship
    Comment in
outcomes validated
false
pmid
26968359
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
138f4edc2d7e5814c3de4d6bb583a76661654f7e0df7813be4b8ae1ec1dfd230
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Apr
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26968359/
title
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

Preserved source evidence · Not medical advice